2022
DOI: 10.1007/s00101-022-01118-7
|View full text |Cite
|
Sign up to set email alerts
|

Liposomales Bupivacain – kein Durchbruch in der postoperativen Schmerztherapie

Abstract: ZusammenfassungEine der größten Limitationen in der Anwendung von Lokalanästhetika liegt in ihrer begrenzten Wirkdauer. In den letzten Jahren wurden liposomale Formulierungen mit prolongierter Freisetzungskinetik entwickelt, um die pharmakologische Wirkdauer der einzeitigen peripheren Regionalanästhesie („Single-shot-Verfahren“) zeitlich „zu strecken“ und somit eine verlängerte Therapiedauer zu bewirken. Im Fokus stehen hierbei insbesondere das Erreichen einer postoperativen Schmerzfreiheit von mindestens 24 h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 67 publications
0
2
0
Order By: Relevance
“…The various local anesthetic delivery systems and their applications are summarized in Table 1 . In recent years, although domestic and foreign research in drug sustained-release formulations has made certain advancements, especially in the fields of antitumor drugs and antibiotics, and the FDA has also approved four types of local anesthetic-related retardant dosage forms, Exparel™, Xaracoll™, Posimir™, and Zynrelef™, for clinical applications, but their clinical translation still faces difficulties (Cusack et al., 2012 ; Hadj et al., 2012 ; Alijanipour et al., 2017 ; Amundson et al., 2017 ; Coppens et al., 2019 ; Velanovich et al., 2019 ; Nair et al., 2020 ; Blair, 2021 ; Chaurasiya et al., 2021 ; Leiman et al., 2021 ; Pedoto et al., 2021 ; Ekelund et al., 2022 ; Otremba et al., 2022 ; Gailey & Ostrum, 2023 ; Yu et al., 2023 ) ( Table 2 ). In recent years, local anesthetic control agents have also proliferated, such as mesoporous silica-coated gold nanorods controlled by infrared light and thermosensitive graphene oxide/chitosan-based nanocomposite hydrogels in local anesthetics; however, no FDA-approved local anesthetic control agents are available for clinical applications (Wang H et al., 2021 ; Al Homsi et al., 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…The various local anesthetic delivery systems and their applications are summarized in Table 1 . In recent years, although domestic and foreign research in drug sustained-release formulations has made certain advancements, especially in the fields of antitumor drugs and antibiotics, and the FDA has also approved four types of local anesthetic-related retardant dosage forms, Exparel™, Xaracoll™, Posimir™, and Zynrelef™, for clinical applications, but their clinical translation still faces difficulties (Cusack et al., 2012 ; Hadj et al., 2012 ; Alijanipour et al., 2017 ; Amundson et al., 2017 ; Coppens et al., 2019 ; Velanovich et al., 2019 ; Nair et al., 2020 ; Blair, 2021 ; Chaurasiya et al., 2021 ; Leiman et al., 2021 ; Pedoto et al., 2021 ; Ekelund et al., 2022 ; Otremba et al., 2022 ; Gailey & Ostrum, 2023 ; Yu et al., 2023 ) ( Table 2 ). In recent years, local anesthetic control agents have also proliferated, such as mesoporous silica-coated gold nanorods controlled by infrared light and thermosensitive graphene oxide/chitosan-based nanocomposite hydrogels in local anesthetics; however, no FDA-approved local anesthetic control agents are available for clinical applications (Wang H et al., 2021 ; Al Homsi et al., 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…During this time, innumerable case series and investigations comparing liposomal with plain bupivacaine have been conducted 34,102–107 . However, the authors of a systematic review and meta-analysis published in 2021 point out that many of the studies with positive findings for liposomal bupivacaine have industry-sponsored authors and/or gaps in data precluding sound conclusions from being made 104,108 .…”
Section: Controversiesmentioning
confidence: 99%